New drug AION-301 aims to slow kidney disease progression

NCT ID NCT06721143

Recruiting now Disease control Sponsor: AION Healthspan, Inc. Source: ClinicalTrials.gov ↗

First seen Apr 17, 2026 · Last updated May 20, 2026 · Updated 7 times

Summary

This study tests whether AION-301, given as two intravenous infusions, is safe and can help adults with Stage 3 chronic kidney disease (CKD). Researchers will compare AION-301 to a placebo to see if it reduces symptoms or slows kidney decline. About 36 participants will receive the drug or placebo, along with oral vitamins, and be followed for up to 24 months.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC KIDNEY DISEASE STAGE 3 are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

SouthCoast Research Center, Inc.
RECRUITING

Miami, Florida, 33136, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••
University of Miami, Leonard M. Miller School of Medicine
RECRUITING

Miami, Florida, 33136, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

CHRONIC KIDNEY DISEASE STAGE 3